|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Flecainide#Adult Indications and Dosage]] |
| {{Flecainide}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| | |
| In patients without structural heart disease, flecainide acetate is indicated for the prevention of
| |
| | |
| – paroxysmal supraventricular [[tachycardia]]s (PSVT), including atrioventricular nodal reentrant [[tachycardia]] atrioventricular reentrant [[tachycardia]] and other supraventricular [[tachycardia]] of unspecified mechanism associated with disabling symptoms
| |
| | |
| – paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms
| |
| | |
| Flecainide acetate is also indicated for the prevention of | |
| | |
| – documented [[ventricular arrhythmia]]s, such as sustained ventricular [[tachycardia]] (sustained VT), that in the judgment of the physician are life-threatening.
| |
| | |
| Use of flecainide acetate for the treatment of sustained VT, like other [[antiarrhythmic]] , should be initiated in the hospital. The use of flecainide acetate is not recommended in patients with less severe [[ventricular arrhythmia]] even if the patients are symptomatic.
| |
| | |
| Because of the proarrhythmic effects of flecainide acetate, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks.
| |
| | |
| Flecainide acetate should not be used in patients with recent [[myocardial infarction]]. (See Boxed WARNINGS.)
| |
| | |
| Use of flecainide acetate in chronic [[atrial fibrillation]] has not been adequately studied and is not recommended. (See Boxed WARNINGS.)
| |
| | |
| As is the case for other [[antiarrhythmic]] agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival or the incidence of sudden death.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = FLECAINIDE ACETATE TABLET [APOTEX CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=72595783-e6a0-6b7a-f428-9ca03d707794#nlm34084-4 | publisher = | date = | accessdate = 11 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| {{Antiarrhythmic agents}}
| |
| | |
| [[Category:Antiarrhythmic agents]]
| |
| [[Category:Piperidines]]
| |
| [[Category:Benzamides]]
| |
| [[Category:Phenol ethers]]
| |
| [[Category:Organofluorides]]
| |
| [[Category:Sodium channel blockers]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |